Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02780310 · ClinicalTrials.gov registry record · Phase 2
Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma
A Phase 2 study of Adenoid Cystic Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 6
- Study locations
NCT02780310 is a Phase 2 study of Adenoid Cystic Carcinoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 33 participants, below the 126-participant average among 16 other Adenoid Cystic Carcinoma trials with a reported enrollment target (74% lower). The trial reports 6 study locations across 2 states.
The verdict
NCT02780310, a Phase 2 study of Adenoid Cystic Carcinoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to find out what effects, good and/or bad, the drug lenvatinib has on the patient and on adenoid cystic carcinoma. This type of cancer study is called a phase II study. Researchers hope to learn if the study drug will shrink the cancer by at least one-quarter compared to its present size. Lenvatinib is an oral medication that can interfere with cancer cell growth and reduce the growth of blood vessels around tumors. This study will help find out if lenvatinib is a useful drug for treating patients with adenoid cystic carcinomas.
Conditions Studied
Interventions
- DRUG Lenvatinib
Study Locations (6)
New York
- Memorial Sloan Kettering Cancer Center @ Suffolk - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering at Mercy Medical Center - Rockville Centre
New Jersey
- Memorial Sloan Kettering Cancer Center - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2016-05-19 |
| Est. Completion | 2026-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02780310
The ClinicalTrials.gov registry entry for NCT02780310 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 126-participant average among 16 other Adenoid Cystic Carcinoma trials with a reported enrollment target (74% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Adenoid Cystic Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Lenvatinib is the first listed.
NCT02780310 reports 6 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT02780310 about?
NCT02780310 is a clinical study titled "Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma". The purpose of this study is to find out what effects, good and/or bad, the drug lenvatinib has on the patient and on adenoid cystic carcinoma. This type of cancer study is called a phase II study. Researchers hope to learn if the study drug will shrink the cancer by at least one-quarter compared to...
What is the current status of trial NCT02780310?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2016-05-19. Estimated completion is 2026-05.
What conditions does trial NCT02780310 study?
This clinical trial studies the following conditions: Adenoid Cystic Carcinoma.
What interventions are being tested in trial NCT02780310?
The interventions under investigation include: Lenvatinib (DRUG).
Who is sponsoring clinical trial NCT02780310?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02780310 being conducted?
This trial has 6 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenoid Cystic Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers
RECRUITING · Phase 2
-
A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma
RECRUITING · Phase 2
-
9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
ACTIVE NOT RECRUITING · Phase 2
-
Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
ACTIVE NOT RECRUITING · Phase 2
-
MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.